Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether sco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jabbour, Elias, Jones, Daniel, Kantarjian, Hagop M., O'Brien, Susan, Tam, Constantine, Koller, Charles, Burger, Jan A., Borthakur, Gautam, Wierda, William G., Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2009
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186638/
https://ncbi.nlm.nih.gov/pubmed/19567878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-01-197715
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados